Skip to main content

Combo Treatment With Xalnesiran Shows Promise in Patients With Hep B

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 16, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 13, 2024 -- For patients with chronic hepatitis B virus (HBV) infection with virologic suppression with nucleoside or nucleotide analog (NA) therapy, xalnesiran plus an immunomodulator results in a substantial percentage of patients with hepatitis B surface antigen (HBsAg) loss, according to a study published in the Dec. 5 issue of the New England Journal of Medicine.

Jinlin Hou, M.D., from Nanfang Hospital in Guangzhou, China, and colleagues conducted a phase 2 multicenter, randomized, controlled trial involving adult patients with chronic HBV infection with virologic suppression with NA therapy to examine 48 weeks of treatment with xalnesiran 100 mg (group 1; 30 patients), xalnesiran 200 mg (group 2; 30 patients), xalnesiran 200 mg + ruzotolimod (group 3; 34 patients), xalnesiran 200 mg + pegylated interferon alfa-2a 180 µg (group 4; 30 patients), or NA alone (group 5; 35 patients). The primary efficacy end point was HBsAg loss at 24 weeks after the end of treatment.

The researchers found that a primary end point event occurred in 7, 3, 12, 23, and 0 percent of patients in groups 1, 2, 3, 4, and 5, respectively. At 24 weeks after the end of treatment, HBsAg seroconversion occurred in 3, 0, 3, 20, and 0 percent of participants, respectively. Only participants with a screening HBsAg level below 1,000 IU/mL had HBsAg loss with or without seroconversion.

"Despite the high percentages of participants with HBsAg loss that were observed in the immunomodulatory-therapy groups at the end of treatment, erosion of this response was observed during the follow-up period," the authors write.

The study was funded by F. Hoffmann-La Roche, which is developing xalnesiran.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Seroprevalence of HPAI A(H5) Identified in Bovine Veterinary Practitioners

FRIDAY, Feb. 14, 2025 -- Seroprevalence of highly pathogenic avian influenza (HPAI) A(H5) virus infection has been identified among bovine veterinary practitioners, according to...

PTLD Up for Seronegative Recipients of Epstein-Barr Virus-Seropositive Donor Kidneys

WEDNESDAY, Feb. 5, 2025 -- Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+/R−) kidneys have an increased risk for posttransplant...

COVID-19 Linked to More Severe Outcomes Than Flu, RSV in 2022-2023 Season

THURSDAY, Jan. 30, 2025 -- COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season, according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.